PMID: 9551225Jan 1, 1997Paper

Lung cancer

Cancer Chemotherapy and Biological Response Modifiers
H H Hansen, M Rørth

Abstract

In small cell lung cancer (SCLC) combination chemotherapy including agents such as etoposide, teniposide, cisplatinum, carboplatin, and vincristine, doxorubicin, and cyclophosphamide, or ifosfamide continues to be the back-bone of therapy. The epipodophyllotoxin derivatives together with cisplatin or carboplatin are being used increasingly as part of the initial therapy, and these combinations are by most investigators considered standard therapy. Complete plus partial responses to combination therapy occur in 80-90% of all patients with a median duration of 9-12 months. The median survival in these studies is at present 11-18 months depending on the initial tumour stage. The 5-year survival data remain still around 5% including a small fraction of patients (2%) initially presenting with extensive disease. The tendency is to shorten the duration of treatment to 5-8 months. The results of intensifying the treatment with the use of haematopoietic growth factors continue to be disappointing, although these are not conclusive. With respect to squamous cell carcinoma, adenocarcinoma, and large cell carcinoma several meta-analyses indicate that there is a statistically significant, albeit small advantage favouring cisplatinum contain...Continue Reading

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Related Papers

Cancer Chemotherapy and Biological Response Modifiers
H H Hansen, M Rørth
Cancer Chemotherapy and Biological Response Modifiers
H H Hansen, M Rørth
Cancer Chemotherapy and Biological Response Modifiers
H H Hansen, M Rørth
Cancer Chemotherapy and Biological Response Modifiers
H H Hansen, M Rørth
Cancer Chemotherapy and Biological Response Modifiers
H H Hansen, M Rørth
© 2022 Meta ULC. All rights reserved